UCB0599
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Parkinson's Disease (PD) | A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease | Phase 2 |
PD0053
Completed |
NCT04658186 2020-003265-19 |
Price D., Khan A., Angers R., Cardenas A., Key-Prato M. et al. Neurology 2022; 98(suppl.18) 74th Annual Meeting of American Academy of Neurology (AAN), April 2-7, 2022; Seattle, USA | ||
| Parkinson's Disease (PD) | An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease | Phase 2 |
PD0055
Ongoing |
NCT05543252 2022-500424-30-00 |